Loading…
Akebia Therapeutics, Inc. is projected to rise to $1.54 by 2027, a +17% move from its current price of $1.32. AKBA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.28 | $1.32 | $1.36 | +0.07% |
| Aug 4 | $1.27 | $1.32 | $1.38 | +0.13% |
| Aug 5 | $1.25 | $1.32 | $1.39 | +0.20% |
| Aug 6 | $1.25 | $1.32 | $1.41 | +0.27% |
| Aug 7 | $1.24 | $1.32 | $1.42 | +0.34% |
| Aug 8 | $1.23 | $1.33 | $1.43 | +0.41% |
| Aug 9 | $1.22 | $1.33 | $1.44 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.22 | $1.33 | $1.44 | +0.47% |
| Week 2 | $1.19 | $1.33 | $1.49 | +0.95% |
| Week 3 | $1.16 | $1.34 | $1.54 | +1.42% |
| Week 4 | $1.15 | $1.35 | $1.58 | +1.90% |
| Week 5 | $1.13 | $1.35 | $1.62 | +2.39% |
| Week 6 | $1.11 | $1.36 | $1.65 | +2.87% |
| Week 7 | $1.10 | $1.36 | $1.69 | +3.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics is a biopharmaceutical company focused on kidney-disease therapeutics. Its shares currently trade at $1.28 and the company has a market capitalization of $343.37M. It is ranked 3169 by market capitalization among all publicly traded assets.
The forecasted price path is mixed in the near term but turns increasingly bullish in the longer term, with higher average prices projected for 2040 and 2050 and sizable upside potential reflected in the 2031–2035 period.
A major floor 33.9% below — a decisive break under it would weaken the trend.
The nearest floor, 21.2% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 25.3% above — clearing it would confirm fresh momentum.
Key AKBA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKBA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.30 | Buy | $1.30 | Buy |
| MA 10 | $1.28 | Buy | $1.30 | Buy |
| MA 20 | $1.33 | Sell | $1.28 | Buy |
| MA 50 | $1.15 | Buy | $1.23 | Buy |
| MA 100 | $1.25 | Buy | $1.29 | Buy |
| MA 200 | $1.48 | Sell | $1.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.31 | Neutral |
| Stoch RSI (14) | 38.88 | Neutral |
| CCI (20) | -9.86 | Neutral |
| Williams %R (14) | -44.44 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -4.35 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 55.56 | Neutral |
| TRIX (15) | 0.58 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 56.92 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 1.32 | Sell |
| ADX (14) | 18.79 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is labeled bullish. The RSI(14) is 50, and the stock trades around the 50-day average near $1.12 while remaining below the 200-day average at $1.55. The current price of $1.28 sits above the 50-day average but below the 200-day average.
The 30-day price range runs from $1.04 to $1.58, with technical support at $0.873 and resistance at $1.43.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.873 | $1.32 | $1.86 | 0% | Neutral | |
| $1.22 | $1.54 | $2.07 | +17% | Neutral | |
| $1.35 | $1.77 | $2.48 | +34% | Bullish | |
| $1.43 | $1.92 | $2.78 | +46% | Bullish | |
| $1.42 | $1.95 | $2.89 | +48% | Bullish | |
| $1.76 | $2.47 | $3.76 | +87% | Bullish | |
| $2.16 | $3.09 | $4.80 | +134% | Bullish | |
| $2.31 | $3.37 | $5.33 | +155% | Bullish | |
| $2.36 | $3.50 | $5.64 | +165% | Bullish | |
| $2.37 | $3.58 | $5.86 | +171% | Bullish | |
| $3.70 | $6.04 | $10.57 | +358% | Bullish | |
| $5.92 | $11.08 | $21.35 | +739% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.873 | $1.32 | $1.67 | +0.00% |
| September 2026 | $1.20 | $1.42 | $1.74 | +7.95% |
| October 2026 | $1.17 | $1.40 | $1.74 | -1.50% |
| November 2026 | $1.18 | $1.42 | $1.78 | +1.39% |
| December 2026 | $1.22 | $1.48 | $1.86 | +3.70% |
Click any year to see its month-by-month AKBA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akebia Therapeutics, Inc.'s 2026 outlook centres on $1.32, within a $0.873 to $1.86 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, AKBA could reach as high as $2.07, with a base case around $1.54 and support toward $1.22 — roughly +17% from $1.32. A consolidation phase looks the most probable path here.
Expect AKBA to range from $1.35 to $2.48 through 2028. The $1.77 average target implies a +34% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The AKBA price prediction for 2029 points to an average of $1.92 (low $1.43, high $2.78) — a potential gain of +46% on today's $1.32. Buyers look set to stay in control over this stretch.
In 2030, AKBA is projected to trade between $1.42 and $2.89, averaging $1.95 — a potential gain of +48% from today's $1.32. That is up +1% on the projected 2029 average. Momentum favours further upside here.
Akebia Therapeutics, Inc.'s 2031 outlook centres on $2.47, within a $1.76 to $3.76 range. That is up +27% on the projected 2030 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, AKBA could reach as high as $4.80, with a base case around $3.09 and support toward $2.16 — roughly +134% from $1.32. Momentum favours further upside here.
Expect AKBA to range from $2.31 to $5.33 through 2033. The $3.37 average target implies a +155% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The AKBA price prediction for 2034 points to an average of $3.50 (low $2.36, high $5.64) — a potential gain of +165% on today's $1.32. Momentum favours further upside here.
In 2035, AKBA is projected to trade between $2.37 and $5.86, averaging $3.58 — a potential gain of +171% from today's $1.32. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Akebia Therapeutics, Inc.'s 2040 outlook centres on $6.04, within a $3.70 to $10.57 range. That is up +69% on the projected 2035 average. That marks a +358% change versus current levels. Momentum favours further upside here.
By 2050, AKBA could reach as high as $21.35, with a base case around $11.08 and support toward $5.92 — roughly +739% from $1.32. Buyers look set to stay in control over this stretch.
Investing $1,000 in AKBA today (≈ 757.575758 AKBA) could be worth
$8,394.72
+$7,394.72 (+739%) by 2050 · US Dollar
Based on the average projected AKBA price of $11.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKBAwould be worth at today's price.
$1,000 invested in AKBA on Jul 31, 2025 (≈ 271.370425 AKBA) would be worth
$358.21
-$641.79 (-64.2%) today · 0.36× · US Dollar
Based on a AKBA entry price of $3.68 vs. today's $1.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.22 | $1,081.97 | +8.2% |
| 1 month ago | $1.21 | $1,090.91 | +9.1% |
| 3 months ago | $1.4 | $942.86 | -5.7% |
| 6 months ago | $1.38 | $956.52 | -4.3% |
| 1 year ago | $3.68 | $358.21 | -64.2% |
| All time (5.0y) ago | $2.57 | $513.62 | -48.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKBA forecast.
Our base-case forecast reaches $2.60 around 2032.
Implied market cap at $2.60: $697.47M
The multi-year forecast shows a path of gradual upside with a notable acceleration later in the period. For 2026 the min/avg/max are $0.873/$1.28/$1.82 (avg $1.28). The forecast continues with 2027 at $1.16/$1.48/$2.00 (avg $1.48, ROI 15.5%), 2028 at $1.31/$1.72/$2.43 (avg $1.72, ROI 34.4%), and 2029 at $1.35/$1.83/$2.68 (avg $1.83, ROI 43.3%), culminating in 2030 at $1.30/$1.81/$2.72 (avg $1.81, ROI 41.3%).
By 2031 the average advances to $2.39 (ROI 86.9%), 2032 to $2.95 (ROI 130.4%), and 2033 to $3.13 (ROI 144.7%), with 2034 averaging $3.34 (ROI 161.2%) and 2035 $3.37 (ROI 163.3%). The longer-horizon forecasts are strongly bullish, with 2040 averaging $5.75 (ROI 349.1%) and 2050 averaging $10.19 (ROI 696.2%). These projections imply meaningful upside but are not guarantees and depend on many factors.
Tap a question to reveal the answer.
The forecast for 2030 shows min $1.30, avg $1.81, max $2.72, with an estimated ROI of 41.3% and a bullish sentiment.
Yes. The 2034 forecast shows max $5.46 and 2035 max $5.59, with 2034 avg $3.34 and 2035 avg $3.37; the sentiment is bullish.
Current price is $1.28 and market cap is $343.37M. The rank is 3169.
The 30-day range is $1.04 to $1.58; RSI(14) is 50; SMA50 is $1.12; SMA200 is $1.55; support sits at $0.873 and resistance at $1.43; sentiment is BULLISH.
For 2030 the average price is $1.81 (min $1.30, max $2.72) with ROI 41.3%. By 2040 the average is $5.75 (ROI 349.1%) and by 2050 the average is $10.19 (ROI 696.2%). The outlook remains bullish, but forecasts are not guarantees.
Akebia Therapeutics, Inc. Community Discussion
0Share your Akebia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.